Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HTI vaccine + vesatolimod
- Development stage
- Unknown
- Lead developer
- Gilead Sciences
- Modality
- Viral Vectors → Gene Addition/Replacement → Gene Therapies, Small Molecules, Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Oral
01
Overview
A combination immunotherapy regimen for the treatment of HIV-1 infection, consisting of the HTI (HIVACAT T-cell immunogen) therapeutic vaccine and the TLR7 agonist vesatolimod (GS-9620). The HTI vaccine is delivered using a prime-boost strategy with recombinant viral vectors—Chimpanzee Adenovirus Oxford 1 (ChAdOx1) and Modified Vaccinia Virus Ankara (MVA)—to elicit a broad and potent T-cell response against conserved regions of the HIV genome. Vesatolimod is an orally administered small molecule that selectively activates Toll-like receptor 7, thereby stimulating innate immune pathways and potentially enhancing the vaccine-induced T-cell response or promoting the clearance of virally infected cells from the reservoir. This combination was developed through a collaboration between Aelix Therapeutics and Gilead Sciences.
- Other names
- HTI vaccine + GS-9620
02
Targets
TLR7 (Toll-like receptor 7)
Beyond the preview
Go deeper on HTI vaccine + vesatolimod.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HTI vaccine + vesatolimod.